2016 Hematological Malignancies

Phase II trial RT and anti-PD1 in early favorable cHL

Classical HL in clinical stage I/II without risk factors* Age 18 - 75

1 x anti-PD-1 antibody #

6 x anti-PD-1 antibody

20 Gy IS-RT §

5 x anti-PD-1 antibody #

20 Gy IS-RT §

* Risk factors: Large med mass, extranodal lesion, elevated ESR, ≥ 3 nodal areas # x mg/kg every 2 weeks § IS-RT starts on day 5 after the first infusion on the anti-PD-1 antibody